Variable | Entire cohort | NS | BES | P-value |
---|---|---|---|---|
Number | 54 | 27 | 27 | – |
Age | 57.8 | 57.9 | 57.8 | 0.557 |
Gender | ||||
 Males | 44 (81.5%) | 21 (38.9%) | 23 (42.6%) | 0.555 |
 Females | 11 (20.4%) | 6 (11.1%) | 5 (9.3%) | |
TNM stage | ||||
 Early | 9 (16.7%) | 5 (9.3%) | 4 (7.4%) | 0.352 |
 Advanced | 46 (85.2%) | 22 (40.7%) | 24 (44.4%) | |
Tumor site | ||||
 Oral cavity | 18 (33.3%) | 10 (18.5%) | 8 (14.8%) | 0.231 |
 Oropharynx | 13 (24.1%) | 7 (13.0%) | 6 (11.1%) | 0.532 |
 Larynx | 12 (22.2%) | 7 (13.0%) | 5 (9.3%) | 0.323 |
 Other | 12 (22.2%) | 7 (13.0%) | 5 (9.3%) | 0.323 |
Charlson Comorbidity Index | 1.57 | 1.43 | 1.63 | 0.754 |
Smoking (Pack-years) | 17.3 | 16.4 | 19.7 | 0.522 |
BMI (kg) | 3.73 | 4.68 | 2.98 | 0.713 |
Radiotherapy | 42 (77.8%) | 22 (40.7%) | 20 (37.0%) | 0.372 |
Chemotherapy | 15 (27.8%) | 5 (9.3%) | 10 (18.5%) | 0.112 |